Skip to search.
 FTSE 100 Up 1.82%

KaloBios Pharmaceuticals, Inc. (KBIO)

-NasdaqGM
3.03 Up 0.99(48.53%) 20:59
|After Hours: : 2.95 Down 0.08 (2.64%) 21:25 - Nasdaq Real Time Price
Add to Portfolio
Prev Close:2.04
Open:2.08
Bid:2.96 x 200
Ask:3.20 x 500
1y Target Est:5.00
Beta:4.11488
Earnings Date:4 Nov - 9 Nov (Est.)
Day's Range:2.08 - 3.67
52wk Range:1.71 - 17.20
Volume:4,023,311
Avg Vol (3m):65,745
Market Cap:12.50m
P/E (ttm):N/A
EPS (ttm):-8.11
Div & Yield:N/A (N/A)
Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.

Headlines

  • No Headlines available for KBIO at this time.

Comparison

Symbol% ChgMkt Cap
KBIOUp 48.53%12.50m
VRTXDown 1.91%30.96b

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):N/A
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-15) :-6.49
Quarterly EPS Est (Sep-15) :-1.45
Mean Recommendation*:1.0
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. more
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback